Calliditas Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Calliditas Therapeutics has a total shareholder equity of SEK120.2M and total debt of SEK986.4M, which brings its debt-to-equity ratio to 821%. Its total assets and total liabilities are SEK1.7B and SEK1.6B respectively.
Key information
821.0%
Debt to equity ratio
kr986.39m
Debt
| Interest coverage ratio | n/a |
| Cash | kr810.32m |
| Equity | kr120.15m |
| Total liabilities | kr1.57b |
| Total assets | kr1.69b |
Recent financial health updates
No updates
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Financial Position Analysis
Short Term Liabilities: CALT's short term assets (SEK1.1B) exceed its short term liabilities (SEK408.2M).
Long Term Liabilities: CALT's short term assets (SEK1.1B) do not cover its long term liabilities (SEK1.2B).
Debt to Equity History and Analysis
Debt Level: CALT's net debt to equity ratio (146.5%) is considered high.
Reducing Debt: CALT's debt to equity ratio has increased from 0% to 821% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CALT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.